Arrowhead Pharmaceuticals has filed a New Drug Application with the U.S. FDA for plozasiran to treat Familial Chylomicronemia Syndrome.

Rituximab is a chimeric monoclonal antibody that targets the CD20 antigen found on the surface of B cells.

Seismic Therapeutics showcases new preclinical findings for S-4321, a next-gen bifunctional agonist antibody that targets PD-1 and FcγRIIb.

Mirvetuximab soravtansine is an antibody-drug conjugate (ADC) developed by ImmunoGen, Inc., targeting folate receptor alpha (FRα).

The trial tests TGN-S11 alone and in combination with Keytruda® (pembrolizumab) for stage 4 cancer patients associated with Human Papillomavirus.

Sparsentan is a small molecule drug that targets AT1R x ETA and has been approved for use in the treatment of a variety of therapeutic areas.

Samsung Bioepis and Biogen have obtained approval from the European Commission (EC) for their Aflibercept biosimilar, named OPUVIZ.

Loncastuximab tesirine is an antibody-drug conjugate (ADC) developed by ADC Therapeutics, targeting CD19, a protein that is expressed on the surface of B cells.

Bluejay Therapeutics, has revealed new findings from its Phase 2 trial of BJT-778.

Zanubrutinib is a small molecule drug that targets the BTK enzyme and is approved for use in various therapeutic areas including neoplasms.

Acepodia has received FDA approval for the Investigational New Drug Application of ACE1831 to treat IgG4-related disease.

Retifanlimab, a groundbreaking therapeutic agent, is a fully humanized monoclonal antibody developed by Incyte Corporation.